The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information.
作者信息
Schiestl Martin, Krendyukov Andriy
机构信息
Sandoz GmbH, Kundl, Austria.
Sandoz Biopharmaceuticals,Hexal AG, Holzkirchen, Germany.
出版信息
ESMO Open. 2017 Aug 17;2(3):e000245. doi: 10.1136/esmoopen-2017-000245. eCollection 2017.
Abstract
摘要
相似文献
1
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information.欧洲肿瘤内科学会（ESMO）关于肿瘤学中生物类似药的立场文件：加强提供准确的教育和信息。
ESMO Open. 2017 Aug 17;2(3):e000245. doi: 10.1136/esmoopen-2017-000245. eCollection 2017.
2
Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology.肿瘤学中生物类似药的知识与应用：欧洲医学肿瘤学会的一项调查
ESMO Open. 2019 Mar 6;4(2):e000460. doi: 10.1136/esmoopen-2018-000460. eCollection 2019.
3
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.生物类似药：欧洲医学肿瘤学会立场文件，特别涉及肿瘤学开方医生
ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016.
4
Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.FDA 生物类似药外推框架在标签外使用的判定。
J Manag Care Spec Pharm. 2017 Dec;23(12):1227-1232. doi: 10.18553/jmcp.2017.23.12.1227.
5
[Biosimilar drugs in oncology].[肿瘤学中的生物类似药]
Bull Cancer. 2016 Mar;103(3):294-8. doi: 10.1016/j.bulcan.2015.12.004. Epub 2016 Jan 29.
6
Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodies.肿瘤学中的生物类似药：粒细胞集落刺激因子十年经验及其对单克隆抗体的启示
Crit Rev Oncol Hematol. 2019 Jul 23:102785. doi: 10.1016/j.critrevonc.2019.07.009.
7
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis.肿瘤生物类似药的比较安全性概况：系统评价与网状Meta分析
BioDrugs. 2023 Mar;37(2):205-218. doi: 10.1007/s40259-023-00576-8. Epub 2023 Feb 2.
8
Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective.生物类似药在沙特阿拉伯肿瘤血液学中的新兴作用：实践视角
Glob J Qual Saf Healthc. 2019 Dec 12;3(1):22-29. doi: 10.4103/JQSH.JQSH_15_19. eCollection 2020 Feb.
9
Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.生物类似药在乳腺癌治疗中的应用：巴西肿瘤学家意见、实践和关注的全国性调查。
JCO Glob Oncol. 2021 Aug;7:1316-1324. doi: 10.1200/GO.20.00649.
10
Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies.生物类似药的使用：对卫生组织和学会发布的立场声明和建议的系统评价。
BioDrugs. 2024 May;38(3):405-423. doi: 10.1007/s40259-024-00649-2. Epub 2024 Mar 12.
引用本文的文献
1
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review.利用定向文献综述的结果定义可持续全球生物类似药市场的框架。
BioDrugs. 2025 May;39(3):411-425. doi: 10.1007/s40259-025-00710-8. Epub 2025 Feb 26.
2
Monoclonal antibody biosimilars for cancer treatment.用于癌症治疗的单克隆抗体生物类似药。
iScience. 2024 May 24;27(6):110115. doi: 10.1016/j.isci.2024.110115. eCollection 2024 Jun 21.
3
Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP.在 REFLECT 中评估弥漫性大 B 细胞淋巴瘤（DLBCL）的生活质量：一项前瞻性、非干预性、多中心、德国研究，评估 Sandoz 利妥昔单抗联合 CHOP 方案的疗效。
Ann Hematol. 2024 Aug;103(8):3165-3178. doi: 10.1007/s00277-024-05850-5. Epub 2024 Jun 20.
4
Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.引入曲妥珠单抗生物类似药治疗中国 HER2 阳性乳腺癌的预算影响分析。
Clin Drug Investig. 2022 Nov;42(11):937-947. doi: 10.1007/s40261-022-01197-9. Epub 2022 Sep 17.
5
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.高级从业者将肿瘤生物类似药疗法融入实践的实用策略精简版
J Adv Pract Oncol. 2022 May;13(4):417-439. doi: 10.6004/jadpro.2022.13.4.5. Epub 2022 Jun 21.
6
Extrapolation concept at work with biosimilar: a decade of experience in oncology.生物类似药的外推概念应用：肿瘤学领域十年经验
ESMO Open. 2018 Feb 6;3(2):e000319. doi: 10.1136/esmoopen-2017-000319. eCollection 2018.
7
Policies for biosimilar uptake in Europe: An overview.欧洲生物类似药采用政策概述
PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017.
本文引用的文献
1
Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers.生物类似药：欧洲医学肿瘤学会立场文件，特别涉及肿瘤学开方医生
ESMO Open. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016.
2
Interchangeability of Biosimilars: A European Perspective.生物类似药的可互换性：欧洲视角
BioDrugs. 2017 Apr;31(2):83-91. doi: 10.1007/s40259-017-0210-0.
3
European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars.欧洲药品管理局生物药品指南：安全使用生物类似药的进一步举措。
Clin Mol Allergy. 2015 May 15;13(1):3. doi: 10.1186/s12948-015-0010-3. eCollection 2015.
4
Biosimilars: the science of extrapolation.生物类似药：外推科学。
Blood. 2014 Nov 20;124(22):3191-6. doi: 10.1182/blood-2014-06-583617. Epub 2014 Oct 8.
5
Biosimilars: what clinicians should know.生物类似药：临床医生应知应会
Blood. 2012 Dec 20;120(26):5111-7. doi: 10.1182/blood-2012-04-425744. Epub 2012 Oct 23.
6
The state of the art in the development of biosimilars.生物类似药研发的最新进展。
Clin Pharmacol Ther. 2012 Mar;91(3):405-17. doi: 10.1038/clpt.2011.343. Epub 2012 Feb 8.
Zotero 插件